Creso Pharma Ltd.’s Share Mounted on ASX

ecefda creso pharma ipo

Entered into the Frankfurt Stock Exchange Trading Platform: Creso Pharma Limited’s (ASX: CPH) stock climbed up 1.562 per cent on July 18, 2018 after the announcement of its listing on the Frankfurt Stock Exchange following the successful, revenue-generating dual product launch of cannaQIX and anibidiol and initial sales orders in Europe’s Benelux region wherein the group reported first revenues of CHF 230,000 (A$311,940) from cannaQIX along with sales of Creso’s animal health product, anibidiol. According to the announcement, the European investors can trade the Company’s ordinary shares under the stock code of “1X8” on the Frankfurt Stock Exchange. Besides this, the group has hired Deutsche Gesellschaft für Wertpapieranalyse GmbH (DGWA) as a German Corporate Advisor to take care of its European investor relations strategy; interact with the German speaking media Environment and assist the retail and institutional investors, and the strategy related to the Frankfurt Stock Exchange listing. Following the appointment of DGWA, the group expects an increase in the stock’s liquidity levels and raise the Company’s profile and promote Creso’s operational activities in the European region. In the June month, the group has also appointed Mr. John Griese as a Chief Operating Officer (COO) for the America region to help establish and expand its footprint in the North America region. Meanwhile, CPH stock climbed up 2.40 per cent in the past one week as on July 17, 2018 and recorded market capitalization of $70.80 Mn.

[pluginops_form template_id=’23834′ ]

 

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report